The exclusive license covers the delivery and use of sustained-release exenatide, a GLP-1 receptor agonist, in the treatment of neurodegenerative disorders, including Parkinson's and Alzheimer's diseases.
This intellectual property was developed as part of a Cooperative Research and Development Agreement (CRADA) between Peptron and the NIH to develop and advance a form of exenatide that effectively crosses the blood-brain barrier and provides sustained release of the neuroprotective peptide to treat degenerative diseases of the central nervous system.
Peptron has developed fundamental technologies for creating sustained-release formulations to develop patient-friendly peptide-based medicines with a high technological entrance barrier and excellent product competitiveness for the treatment of life-threatening and chronic diseases.
Peptron is headquartered in Daejeon, Korea with GMP manufacturing facilities in Osong, Korea.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference